NO20021637L - Kjemikalske forbindelser - Google Patents
Kjemikalske forbindelserInfo
- Publication number
- NO20021637L NO20021637L NO20021637A NO20021637A NO20021637L NO 20021637 L NO20021637 L NO 20021637L NO 20021637 A NO20021637 A NO 20021637A NO 20021637 A NO20021637 A NO 20021637A NO 20021637 L NO20021637 L NO 20021637L
- Authority
- NO
- Norway
- Prior art keywords
- chemical compounds
- compounds
- chemical
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9923748.9A GB9923748D0 (en) | 1999-10-07 | 1999-10-07 | Chemical compounds |
PCT/EP2000/009722 WO2001025219A2 (en) | 1999-10-07 | 2000-10-05 | Piperazine compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20021637D0 NO20021637D0 (no) | 2002-04-05 |
NO20021637L true NO20021637L (no) | 2002-06-06 |
NO323776B1 NO323776B1 (no) | 2007-07-02 |
Family
ID=10862304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021637A NO323776B1 (no) | 1999-10-07 | 2002-04-05 | Piperazinderivater, fremgangsmater for fremstilling av samme, farmasoytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling av medikament |
Country Status (33)
Country | Link |
---|---|
US (6) | US6951861B1 (no) |
EP (3) | EP1460066B1 (no) |
JP (1) | JP4776844B2 (no) |
KR (2) | KR100857671B1 (no) |
CN (1) | CN100413850C (no) |
AR (2) | AR025975A1 (no) |
AT (3) | ATE435215T1 (no) |
AU (1) | AU768780B2 (no) |
BR (1) | BR0014541A (no) |
CA (1) | CA2386515C (no) |
CO (1) | CO5251467A1 (no) |
CY (2) | CY1110172T1 (no) |
CZ (1) | CZ302340B6 (no) |
DE (3) | DE60040176D1 (no) |
DK (3) | DK1218359T3 (no) |
ES (3) | ES2222927T3 (no) |
GB (1) | GB9923748D0 (no) |
HK (3) | HK1052506B (no) |
HU (1) | HUP0203136A3 (no) |
IL (2) | IL148964A0 (no) |
MX (1) | MXPA02003515A (no) |
MY (1) | MY130907A (no) |
NO (1) | NO323776B1 (no) |
NZ (2) | NZ518144A (no) |
PE (1) | PE20010741A1 (no) |
PL (1) | PL201191B1 (no) |
PT (3) | PT1460066E (no) |
SI (3) | SI1454901T1 (no) |
TN (1) | TNSN00194A1 (no) |
TR (1) | TR200200936T2 (no) |
TW (1) | TWI225485B (no) |
WO (1) | WO2001025219A2 (no) |
ZA (1) | ZA200202589B (no) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2327600T3 (es) * | 1999-02-18 | 2009-11-02 | Novasearch Ag | Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas. |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0108595D0 (en) | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
GB0108594D0 (en) * | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
GB0119797D0 (en) | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
GB0124463D0 (en) * | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203022D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
EP1472222A1 (en) | 2002-02-08 | 2004-11-03 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |
DE10209145A1 (de) * | 2002-03-01 | 2003-09-04 | Bayer Cropscience Ag | Halogenbenzole |
WO2003101459A1 (en) * | 2002-05-29 | 2003-12-11 | The Regents Of The University Of California | Antagonizing nk1 receptors inhibits consumption of substances of abuse |
JP4079727B2 (ja) | 2002-09-06 | 2008-04-23 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法 |
EP1594574A2 (en) * | 2003-01-27 | 2005-11-16 | Glaxo Group Limited | Nk1 receptor antagonists for the treatment of functional dyspepsia |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
BRPI0410630A (pt) * | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
US20060148781A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder in a non-human mammal |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
US20060148783A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20070142367A1 (en) * | 2003-11-10 | 2007-06-21 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20050113365A1 (en) * | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
US7390905B2 (en) * | 2003-11-28 | 2008-06-24 | Mitsubishi Tanabe Pharma Corporation | Piperidine compound and process for preparing the same |
US20090186874A1 (en) * | 2004-01-14 | 2009-07-23 | Yoshinori Ikeura | Carboxamide derivative and use thereof |
TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
WO2007042250A1 (en) * | 2005-10-10 | 2007-04-19 | Glaxo Group Limited | Prolinamide derivatives as sodium channel modulators |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP4904945B2 (ja) | 2006-06-30 | 2012-03-28 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体の製造方法 |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
JP5510040B2 (ja) * | 2010-04-28 | 2014-06-04 | セントラル硝子株式会社 | 光学活性(r)−1−(4−フルオロフェニル)エチルアミンを得る光学分割 |
WO2012175434A1 (en) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Pharmaceutical formulations comprising vestipitant |
EP2729147B1 (en) | 2011-07-04 | 2017-09-06 | IRBM - Science Park S.p.A. | Nk-1 receptor antagonists for treating corneal neovascularisation |
RU2631319C2 (ru) | 2012-02-22 | 2017-09-21 | Лео Фарма А/С | Новые соединения - антагонисты рецептора нейрокинина 1 |
WO2015024203A1 (en) | 2013-08-20 | 2015-02-26 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds ii |
WO2016102967A1 (en) | 2014-12-23 | 2016-06-30 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
US10399949B2 (en) | 2015-12-07 | 2019-09-03 | Kissei Pharmaceutical Co., Ltd. | NK1 receptor antagonist |
US11160809B2 (en) | 2017-04-10 | 2021-11-02 | Chase Therapeutics Corporation | NK1-antagonist combination and method for treating synucleinopathies |
BR112019028034A2 (pt) | 2017-06-30 | 2020-07-07 | Chase Therapeutics Corporation | composições de antagonista de nk-1 e métodos para uso no tratamento da depressão |
KR20200061381A (ko) | 2017-10-05 | 2020-06-02 | 바이오젠 인크. | 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4087424A (en) | 1974-05-09 | 1978-05-02 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
US4219554A (en) | 1974-05-09 | 1980-08-26 | Toyama Chemical Company, Limited | Novel penicillins and cephalosporins and process for producing same |
US4112090A (en) | 1974-05-09 | 1978-09-05 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4327097A (en) | 1974-05-09 | 1982-04-27 | Toyama Chemical Co., Ltd. | Novel penicillins |
US4110327A (en) | 1974-05-09 | 1978-08-29 | Toyama Chemical Co., Ltd. | 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives |
US4379152A (en) | 1974-05-09 | 1983-04-05 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4410522A (en) | 1974-05-09 | 1983-10-18 | Toyama Chemical Co., Ltd. | Cephalosporins |
NO154582C (no) | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPS57118587A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel penicillin |
US5028610A (en) | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
GB8709666D0 (en) | 1987-04-23 | 1987-05-28 | Beecham Group Plc | Compounds |
GB8713061D0 (en) | 1987-06-04 | 1987-07-08 | Beecham Group Plc | Compounds |
US5109014A (en) | 1990-12-10 | 1992-04-28 | Jacobson Richard M | N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides |
SE9100860D0 (sv) | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
DE69231395T3 (de) | 1991-09-20 | 2005-07-21 | Glaxo Group Ltd., Greenford | Neue medizinische Indikation für Tachykinin-Antagonisten |
CA2083891A1 (en) | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
AU3085895A (en) | 1994-07-26 | 1996-02-22 | Sankyo Company Limited | N-phenylated amide and urea derivatives |
US5696123A (en) | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
DE19520499C2 (de) | 1994-09-17 | 2003-06-18 | Boehringer Ingelheim Kg | Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung |
DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
US5576317A (en) | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
EP0799202A1 (de) | 1994-12-23 | 1997-10-08 | Dr. Karl Thomae GmbH | Piperazinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
DE19608665A1 (de) | 1996-03-06 | 1997-09-11 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
US6057323A (en) | 1996-03-08 | 2000-05-02 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
EP0921801A1 (en) | 1996-04-03 | 1999-06-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0904080A4 (en) | 1996-04-03 | 2001-08-01 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
CA2249604A1 (en) | 1996-04-03 | 1997-10-09 | Theresa M. Williams | Inhibitors of farnesyl-protein transferase |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1998001133A1 (fr) | 1996-07-08 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de la resorption osseuse |
ATE265209T1 (de) * | 1996-07-17 | 2004-05-15 | Merck & Co Inc | Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US5929077A (en) | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
US6114315A (en) | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
US5977104A (en) | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
CA2273856A1 (en) | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating bipolar disorders |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
AU741725B2 (en) | 1997-08-27 | 2001-12-06 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU751950B2 (en) | 1997-11-24 | 2002-09-05 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
TR200101649T2 (tr) * | 1998-12-14 | 2001-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Piperazin türevleri. |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
WO2001030348A1 (en) * | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
US20030022891A1 (en) | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
1999
- 1999-10-07 GB GBGB9923748.9A patent/GB9923748D0/en not_active Ceased
-
2000
- 2000-10-05 KR KR1020077026231A patent/KR100857671B1/ko not_active IP Right Cessation
- 2000-10-05 DE DE60040176T patent/DE60040176D1/de not_active Expired - Lifetime
- 2000-10-05 SI SI200031010T patent/SI1454901T1/sl unknown
- 2000-10-05 ES ES00969414T patent/ES2222927T3/es not_active Expired - Lifetime
- 2000-10-05 SI SI200030492T patent/SI1218359T1/xx unknown
- 2000-10-05 HU HU0203136A patent/HUP0203136A3/hu unknown
- 2000-10-05 CO CO00075822A patent/CO5251467A1/es active IP Right Grant
- 2000-10-05 MY MYPI20004668A patent/MY130907A/en unknown
- 2000-10-05 IL IL14896400A patent/IL148964A0/xx active IP Right Grant
- 2000-10-05 DK DK00969414T patent/DK1218359T3/da active
- 2000-10-05 DE DE60042501T patent/DE60042501D1/de not_active Expired - Lifetime
- 2000-10-05 AU AU79139/00A patent/AU768780B2/en not_active Ceased
- 2000-10-05 CA CA2386515A patent/CA2386515C/en not_active Expired - Lifetime
- 2000-10-05 AT AT04076632T patent/ATE435215T1/de active
- 2000-10-05 US US10/089,964 patent/US6951861B1/en not_active Expired - Lifetime
- 2000-10-05 PT PT04076632T patent/PT1460066E/pt unknown
- 2000-10-05 NZ NZ518144A patent/NZ518144A/xx not_active IP Right Cessation
- 2000-10-05 DK DK04076632T patent/DK1460066T3/da active
- 2000-10-05 ES ES04076632T patent/ES2329130T3/es not_active Expired - Lifetime
- 2000-10-05 ES ES04076650T patent/ES2312917T3/es not_active Expired - Lifetime
- 2000-10-05 CZ CZ20021166A patent/CZ302340B6/cs not_active IP Right Cessation
- 2000-10-05 TR TR2002/00936T patent/TR200200936T2/xx unknown
- 2000-10-05 EP EP04076632A patent/EP1460066B1/en not_active Expired - Lifetime
- 2000-10-05 WO PCT/EP2000/009722 patent/WO2001025219A2/en active IP Right Grant
- 2000-10-05 EP EP00969414A patent/EP1218359B1/en not_active Expired - Lifetime
- 2000-10-05 AT AT00969414T patent/ATE270664T1/de active
- 2000-10-05 AT AT04076650T patent/ATE407125T1/de active
- 2000-10-05 KR KR1020027004438A patent/KR100817373B1/ko not_active IP Right Cessation
- 2000-10-05 EP EP04076650A patent/EP1454901B1/en not_active Expired - Lifetime
- 2000-10-05 DE DE60012031T patent/DE60012031T2/de not_active Expired - Lifetime
- 2000-10-05 DK DK04076650T patent/DK1454901T3/da active
- 2000-10-05 NZ NZ531127A patent/NZ531127A/en not_active IP Right Cessation
- 2000-10-05 JP JP2001528165A patent/JP4776844B2/ja not_active Expired - Fee Related
- 2000-10-05 PT PT00969414T patent/PT1218359E/pt unknown
- 2000-10-05 SI SI200031037T patent/SI1460066T1/sl unknown
- 2000-10-05 MX MXPA02003515A patent/MXPA02003515A/es active IP Right Grant
- 2000-10-05 CN CNB008158606A patent/CN100413850C/zh not_active Expired - Fee Related
- 2000-10-05 PT PT04076650T patent/PT1454901E/pt unknown
- 2000-10-05 BR BR0014541-6A patent/BR0014541A/pt not_active Application Discontinuation
- 2000-10-05 PL PL356261A patent/PL201191B1/pl unknown
- 2000-10-06 PE PE2000001068A patent/PE20010741A1/es not_active Application Discontinuation
- 2000-10-06 TN TNTNSN00194A patent/TNSN00194A1/en unknown
- 2000-10-06 AR ARP000105284A patent/AR025975A1/es not_active Application Discontinuation
- 2000-10-07 TW TW089121014A patent/TWI225485B/zh not_active IP Right Cessation
-
2002
- 2002-04-01 IL IL148964A patent/IL148964A/en not_active IP Right Cessation
- 2002-04-03 ZA ZA200202589A patent/ZA200202589B/en unknown
- 2002-04-05 NO NO20021637A patent/NO323776B1/no not_active IP Right Cessation
- 2002-07-03 US US10/190,170 patent/US6642240B2/en not_active Ceased
-
2003
- 2003-07-03 HK HK03104740.2A patent/HK1052506B/zh not_active IP Right Cessation
- 2003-08-08 US US10/637,825 patent/US7071196B2/en not_active Expired - Fee Related
-
2004
- 2004-05-04 US US10/838,838 patent/US20040209893A1/en not_active Abandoned
- 2004-11-06 HK HK04108748A patent/HK1065798A1/xx not_active IP Right Cessation
- 2004-12-01 HK HK04109454.6A patent/HK1066537A1/xx not_active IP Right Cessation
-
2006
- 2006-01-18 US US11/334,267 patent/US7345041B2/en not_active Expired - Fee Related
-
2007
- 2007-12-13 US US11/955,847 patent/US7625904B2/en not_active Expired - Fee Related
-
2008
- 2008-11-27 CY CY20081101376T patent/CY1110172T1/el unknown
-
2009
- 2009-09-18 CY CY20091100969T patent/CY1110104T1/el unknown
-
2010
- 2010-07-15 AR ARP100102567A patent/AR077414A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20021637L (no) | Kjemikalske forbindelser | |
AR028414A1 (es) | Compuestos quimicos | |
EE200100502A (et) | Ühendid | |
DK1326832T3 (da) | Kemiske forbindelser | |
AR028605A1 (es) | Compuesto quimico | |
PT1202994E (pt) | Novos compostos | |
NO20020765L (no) | Kjemiske forbindelser | |
ITMI992711A0 (it) | Composti organici | |
EE200200224A (et) | Uudsed ühendid | |
IS6139A (is) | Ný efnasambönd | |
NO990814L (no) | Kjemiske forbindelser | |
NO20013769L (no) | Kalsilytiske forbindelser | |
NO20020466D0 (no) | Kalsilytiske forbindelser | |
IS6141A (is) | Ný efnasambönd | |
NO20014262D0 (no) | Tiazoloindolinon-forbindelser | |
ID29984A (id) | Senyawa-senyawa bis-stirilbifenil | |
NO993313D0 (no) | Kjemiske forbindelser | |
SE0004925L (sv) | Kemiska föreningar | |
SE0003664D0 (sv) | Chemical compounds | |
AR028304A1 (es) | Compuestos quimicos | |
SE9902762D0 (sv) | New compounds | |
SE9904228D0 (sv) | New compounds | |
SE9904422D0 (sv) | New compounds | |
SE9904420D0 (sv) | New compounds | |
SE9904418D0 (sv) | New compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
MM1K | Lapsed by not paying the annual fees |